Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Has results × Lambert-Eaton Myasthenic Syndrome × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 753 Carcinoma, Non-Small-Cell Lung 550 Prostatic Neoplasms 448 Multiple Myeloma 368 Neoplasms 366 Leukemia, Myeloid, Acute 328 Lymphoma 306 Leukemia 295 Melanoma 292 Neoplasm Metastasis 291 Lung Neoplasms 273 Leukemia, Lymphocytic, Chronic, B-Cell 268 Lymphoma, Non-Hodgkin 260 Colorectal Neoplasms 242 Ovarian Neoplasms 228 Pancreatic Neoplasms 220 Recurrence 211 Precursor Cell Lymphoblastic Leukemia-Lymphoma 206 Myelodysplastic Syndromes 205 Glioblastoma 190 Brain Neoplasms 177 Lymphoma, Follicular 173 Lymphoma, Large B-Cell, Diffuse 172 Hodgkin Disease 170 Carcinoma, Renal Cell 166 Squamous Cell Carcinoma of Head and Neck 159 Head and Neck Neoplasms 158 Lymphoma, Mantle-Cell 153 Sarcoma 137 Fallopian Tube Neoplasms 120

Interventions

Amifampridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01511978 2017-07-11

DAPPER

Jacobus Pharmaceutical

Phase 2 Completed

32 enrolled 16 charts

Lambert-Eaton Myasthenic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡